Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

The shares of biopharmaceutical firm Biocon fell as much as 2.04 per cent in Tuesday's trading session, figuring among top ...

Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...

Bengaluru's Yellow Line of the Namma Metro, connecting Rashtreeya Vidyalaya Road (RV Road) and Bommasandra, has entered its ...

The US diabetes market presents a substantial opportunity for Biocon Biologics, with 38.4 million people living with diabetes ...

Biocon bagged US FDA's approval for Kristy, which is a rapid-acting human insulin analog, indicated to improve glycemic ...

Biocon Biologics receives USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog, expanding their insulin ...

Biocon Biologics receives USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog. This rapid-acting insulin ...

As per the company’s regulatory filing, Kristy is currently available in the European Union and Canada markets from 2022.

Currently, Kristy is available in the European Union and Canada markets since 2022. The approval is for the fist and only ...

Biocon share price today rose 3% after Biocon Biologics received US FDA approval for diabetes drug Kirsty, the first interchangeable biosimilar to NovoLog in the US. Get latest updates on Biocon ...

The US Food and Drug Administration approved, the first rapid-acting interchangeable biosimilar product, Kirsty (insulin ...